{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:57:25Z","timestamp":1758970645411},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:00:00Z","timestamp":1472083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>In this phase 2, multicenter, parallel\u2010group, double\u2010blind, dose\u2010ranging study, hypertensive adults (n=449) were randomized to receive one of five doses of a capsule formulation of azilsartan medoxomil (<jats:styled-content style=\"fixed-case\">AZL<\/jats:styled-content>\u2010M; 5, 10, 20, 40, 80\u00a0mg), olmesartan medoxomil (<jats:styled-content style=\"fixed-case\">OLM<\/jats:styled-content>) 20\u00a0mg, or placebo once daily. The primary endpoint was change in trough clinic diastolic blood pressure (<jats:styled-content style=\"fixed-case\">DBP<\/jats:styled-content>) at week 8. <jats:styled-content style=\"fixed-case\">AZL<\/jats:styled-content>\u2010M provided rapid statistically and clinically significant reductions in <jats:styled-content style=\"fixed-case\">DBP<\/jats:styled-content> and systolic blood pressure (<jats:styled-content style=\"fixed-case\">SBP<\/jats:styled-content>) vs placebo at all doses except 5\u00a0mg. Placebo\u2010subtracted changes were greatest with the 40\u00a0mg dose (<jats:styled-content style=\"fixed-case\">DBP<\/jats:styled-content>, \u22125.7\u00a0mm\u00a0Hg; <jats:styled-content style=\"fixed-case\">SBP<\/jats:styled-content>, \u221212.3\u00a0mm\u00a0Hg). Clinic changes with <jats:styled-content style=\"fixed-case\">AZL<\/jats:styled-content>\u2010M (all doses) were statistically indistinguishable vs <jats:styled-content style=\"fixed-case\">OLM<\/jats:styled-content>, although there were greater reductions with <jats:styled-content style=\"fixed-case\">AZL<\/jats:styled-content>\u2010M 40\u00a0mg using 24\u2010hour ambulatory blood pressure. Adverse event frequency was similar in the <jats:styled-content style=\"fixed-case\">AZL<\/jats:styled-content>\u2010M and placebo groups. Based on these and other findings, subsequent trials investigated the commercial <jats:styled-content style=\"fixed-case\">AZL<\/jats:styled-content>\u2010M tablet in the dose range of 20 to 80\u00a0mg\/d.<\/jats:p>","DOI":"10.1111\/jch.12895","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T10:33:50Z","timestamp":1472121230000},"page":"312-321","source":"Crossref","is-referenced-by-count":8,"title":["The Impact of Azilsartan Medoxomil Treatment (Capsule Formulation) at Doses Ranging From 10 to 80\u00a0mg: Significant, Rapid Reductions in Clinic Diastolic and Systolic Blood Pressure"],"prefix":"10.1111","volume":"19","author":[{"given":"Alfonso","family":"Perez","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas, Inc. Deerfield IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Cao","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. Deerfield IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2010.00360.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2010.03.001"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60685-1"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199921010-00003"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.11.940.34520"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2007.01.060094"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868090-00003"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2011.00518.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S15541"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht151"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_2_7_13_1","unstructured":"Edarbi (Azilsartan Medoxomil) Tablets.U.S. prescribing information. Arbor Pharmaceuticals LLC; Atlanta GA.2014.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/200796s006lbl.pdf. Accessed January 26 2015."},{"key":"e_1_2_7_14_1","unstructured":"Edarbi (Azilsartan Medoxomil) Tablets.Summary of product characteristics. Takeda Pharma A\/S; Taastrup Denmark.2014.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002293\/WC500119204.pdf. Accessed January 26 2015."},{"key":"e_1_2_7_15_1","first-page":"634","article-title":"Azilsartan medoxomil (edarbi): the eighth angiotensin II receptor blocker","volume":"36","author":"Jones JD","year":"2011","journal-title":"P T"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.769521"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q468"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261917"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.10.007"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S22595"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.112.007278"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.176636"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1470320313482170"},{"key":"e_1_2_7_24_1","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and\u00a0Research.Azilsartan Medoxomil (Edarbi) NDA 200\u2010796 Clinical Pharmacology and Biopharmaceutics Review.2011.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/200796Orig1s000ClinPharmR.pdf. Accessed August 19 2014."},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2010.00425.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2011.00482.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.163402"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000170138.56903.7a"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328322cd62"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02356.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2013.39"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/00129784-200707050-00004"},{"key":"e_1_2_7_33_1","unstructured":"Benicar (Olmesartan Medoxomil) Tablets.U.S. prescribing information. Daiichi Sankyo Inc.; Parsippany NJ.2014.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021286s032lbl.pdf. Accessed January 28 2015."},{"key":"e_1_2_7_34_1","unstructured":"Diovan (Valsartan) Tablets.U.S. prescribing information. Novartis Pharmaceuticals Corp.; East Hanover NJ.2014.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021283s041s044lbl.pdf. Accessed January 28 2015."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2012.8"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12895","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12895","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.12895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T01:29:35Z","timestamp":1694309375000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.12895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/jch.12895"],"URL":"https:\/\/doi.org\/10.1111\/jch.12895","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}